STAA

STAAR Surgical Company - 10-Q Summary

Business Context and Reporting Period

Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 3, 2009
Business Overview: STAAR develops, manufactures, and sells visual implants (Intraocular Lenses and Implantable Collamer Lenses) and ophthalmic surgical products. Operations are global, with significant revenue derived from international markets (Germany, Japan, Korea, etc.).

Key Financial Metrics

Note: Debt includes Line of Credit ($2.7M), Capital Leases ($2.2M), and Note Payable ($4.3M).

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 7.5% for the quarter and 3.2% for the six-month period compared to the prior year. This was driven by a decrease in "Other Surgical Products" sales and unfavorable foreign currency exchange rates (specifically the Euro).
• Improved Profitability: Despite lower sales, the operating loss narrowed significantly (down 83.2% for the six-month period). This improvement is attributed to aggressive cost-cutting measures (reductions in marketing, selling, and R&D expenses) and an improved gross margin (56.2% vs. 49.9% prior year).
• Cash Flow Turnaround: The company generated positive cash flow from operations ($0.3M) for the quarter ended July 3, 2009, a significant improvement from the $2.8M cash used in the same period in 2008. For the six months, cash used in operations was only $0.2M compared to $6.1M in the prior year.
• Capital Raise: In June 2009, the company completed a public offering raising $8.5 million. Proceeds were primarily used to post a $7.3 million restricted cash deposit to stay enforcement of a $4.9 million adverse judgment in the Parallax litigation.

Outlook, Risks, and Contingencies

• Going Concern Status: While the company previously faced substantial doubt regarding its ability to continue as a going concern, management believes this doubt has been alleviated due to the equity raise, improved cash flow, and the resolution of the immediate liquidity crisis related to the Parallax judgment.
• Litigation Risks:
  • Parallax Medical Systems: A $4.9 million judgment is on appeal. A $7.3 million deposit is restricted with the court. If the appeal fails, the company must pay the judgment plus interest.
  • Scott C. Moody, Inc.: A similar lawsuit is scheduled for trial on October 19, 2009. The company cannot estimate potential losses, but a material adverse judgment could exceed available cash resources.
• Debt Obligations: The company has a $5 million Senior Secured Promissory Note due December 14, 2010. Interest is currently accruing at 20% per annum (due to the Parallax judgment default status), though this may be reduced to 7% if the judgment is resolved. Additionally, $6.8 million in Series A Preferred Stock is redeemable starting December 29, 2010.
• Regulatory Progress: The FDA removed an "integrity hold" on the company's clinical data on July 21, 2009, allowing the resumption of review for the Visian Toric ICL (TICL) approval. The company also received CE Mark approval for the KS-X Preloaded Injector and FDA 510(k) clearance for the Epiphany Injector.

Key Facts for Investor Verification

• Liquidity Position: Verify the sufficiency of unrestricted cash ($5.8M) to cover operating losses and the upcoming $5M debt maturity in December 2010, especially given the 20% interest rate.
• Litigation Exposure: Monitor the outcome of the Moody trial (Oct 2009) and the Parallax appeal, as adverse outcomes could deplete cash reserves.
• Revenue Trends: Assess whether the decline in U.S. ICL sales (due to the recession) and "Other Surgical Products" will continue, or if the shift to higher-margin NTIOLs will stabilize revenue.
• Regulatory Milestones: Track the FDA's decision on the TICL approval, which is critical for future growth in the U.S. refractive market.
• Preferred Stock Redemption: Note the potential $6.8 million cash outflow required for Series A Preferred Stock redemption beginning in late 2010.